• By engaging Outcome, you gain a trusted and committed partner who intimately understands your company, your sector and your potential investors and acquirers. We will bring our expertise to bear, enhance your value and guide you all the way to a successful transaction.

    Oded Ben-Joseph, PhD Managing Director, Outcome Capital

  • They understood our technology and business as well as anyone.

    Victor Esch, PhD President & CEO, DNAe

  • I have worked with Outcome Capital on multiple, complex transactions. They bring strategic insights and operational experience to the table like no other investment bankers I have ever worked with.

    Lisa Dunlea CEO, XableCath

  • Every member of the Outcome team, from Managing Directors to Analysts, is passionate about what they do, providing a unique perspective to strategy development and transactional execution. We believe this is a key aspect of Outcome’s strong record of success.

    Arnie Freedman Managing Director, Outcome Capital

The Outcome multi-disciplinary team consists of professionals with a variety of backgrounds —

former CEOs, entrepreneurs, institutional investors, bankers, scientists  and clinicians — bringing together a diversity of outlooks, experiences, and knowledge that enable Outcome to develop creative insights and secure the best outcomes for its clients.

Meet the Outcome Life Science Industry Team

Highly experienced team of professionals

  • Partners and senior staff which have an average of 20+ years in the life sciences
  • Substantial expertise in licensing, M&A, collaborations, strategic partnerships and business development
  • Experience evaluating legal and IP implications

Deep scientific knowledge

  • Multiple PhD , MD and Masters degree holders within a variety of scientific disciplines (biochemistry, immunology, neuroscience, cancer biology, radiology)
  • Strong understanding of clinical and regulatory pathways; partners have personally conducted clinical trials and brought products to market

Leadership Team

Oded Ben-Joseph, Ph.D., MBA

Managing Director
Oded Ben-Joseph, Ph.D., MBA

Oded Ben-Joseph, Ph.D., MBA

Managing Director LinkedIn

Dr. Ben-Joseph is a Managing Director with Outcome Capital and co-lead of its life sciences and healthcare practice. He brings a unique combination of executive, entrepreneurial, scientific and transactional experience to Outcome Capital and is passionate about assisting cutting-edge life sciences companies in enhancing their strategic value and developing a path to successful liquidity.

Dr. Ben-Joseph also serves on the Board of Directors of life sciences companies: XableCath, a clinical stage medical device innovator developing cost-effective treatment options for peripheral and cardiovascular disease and  ELIOS Vision, a clinical stage ExTra Laser trabeculotomy for the treatment of glaucoma.  Before joining Outcome Capital, Dr. Ben-Joseph was Managing Director at Boston Equity Advisors, a boutique investment banking firm focusing on private equity and merger and acquisition in the therapeutic medical technology sector.  Prior to that, Dr. Ben-Joseph was an Executive-in-Residence at Oxford Bioscience Partners, a life sciences venture capital firm, and CEO and co-founder of Caliber Therapeutics, a company engaged in the development of catheter-based drug delivery products for the intervention of atherosclerotic diseases. His past managerial and entrepreneurial positions also include President and CEO at Deep Vein Medical, an early stage medtech company dedicated to treating deep venous reflux in patients suffering from chronic venous insufficiency, President and CEO of X-Cell Medical, a clinical stage drug/device convergence company engaged in the development of novel stent-based anti-restenotic drugs, President of Ester Neurosciences, a clinical stage biotech company engaged in the development of novel compounds for the treatment of neurological diseases, and co-founder and CEO of Biolight Phototherapy, a company engaged in the development of laser-based medical devices for the treatment of dermatological disorders and allergies.

His academic appointments include Assistant Professor at the Departments of Radiology and Neuroscience at the University of Michigan, a Visiting Associate Professor at Tokushima University in Japan and a Visiting Scientist at Pfizer. Dr. Ben-Joseph has published numerous peer-review scientific papers as well as industry publications and has received numerous awards and scholarships.

Dr. Ben-Joseph graduated with Honors from Imperial College London and received his Ph.D. from the University of Cambridge. He completed his post-doctoral training at the University of Michigan and received an MBA magna cum laude from the University of Bradford. He is a FINRA Securities Representative holding  Series 7, 63 and 79 registration and a Registered Securities Principal holding a Series 24.

Arnold E. Freedman

Managing Director
Arnold E. Freedman

Arnold E. Freedman

Managing Director LinkedIn

Arnie Freedman is a Managing Director with Outcome Capital, and co-lead of its healthcare practice. Mr. Freedman has extensive experience in private equity financing, mergers and acquisitions and preferred securities. His primary focus is in life sciences offerings, including medical devices, diagnostics and drug development. He assists companies with pre-IPO and early stage financing and prepares companies for the rigor required for merger and acquisition activity.

Mr. Freedman has been involved in the management of entrepreneurial businesses for over 25 years, previously as a co-founder and principal in Boston Equity Advisors, LLC, a registered broker-dealer and boutique investment-banking firm. In this company, Mr. Freedman focused on M&A transactions, private placements of debt and equity with institutional investors from the venture capital, private equity, family-foundation and hedge fund community. He uses his knowledge of the private placement process to help clients prepare for the scrutiny of potential investors by conducting a pre-financing review of client operations and corporate structure, recommending changes, assisting management in implementing those changes and preparing documentation investors require including business plans, marketing and insurance reimbursement strategies and financial models. Arnie brings his operating expertise to bear on the advice and counsel he provides to his clients.

Prior to Boston Equity Advisors, Mr. Freedman was the founder and CEO of Rustel, a Russian/American satellite telecommunications company, where he developed an extensive connection to the European investment community. He worked closely and collaborated with investment banking advisors Deutsche Morgan Grenfell, Salomon Brothers, and Creditanstalt International Advisors.

Mr. Freedman is a graduate with honors from the University of Massachusetts. He is a FINRA Registered Securities Representative holding a Series 7, 63 and 79 and a Registered Securities Principal, Series 24.

 

Ellen S. Baron, Ph.D.

Managing Director
Ellen S. Baron, Ph.D.

Ellen S. Baron, Ph.D.

Managing Director LinkedIn

Dr. Ellen Baron brings extensive experience in the private placement of securities for life science companies with deep domain expertise across multiple disciplines in pharmaceutical and biotechnology industries.  Ellen is committed to the success of emerging growth companies bringing nearly 30 years of industry experience with proven deal execution and a unique access to the people, resources and markets that are vital for success. She has been involved in the raise of more than $150M of investment capital and has $2B in deals to her credit from her days in pharma and biotech.

Dr. Baron currently serves on the Board of Directors of Tetragenetics Inc., a Boston-based biotech pioneering antibodies to ion channels, Sixth Element Capital, a UK-based oncology focused venture capital fund and SFH, a Maine-based nutraceutical company.

Dr. Baron was most recently a Managing Director at Healthios Capital Markets, LLC, leading their firm’s biopharmaceutical practice. Prior to that she spent 9 years as Partner at Oxford Bioscience Partners, a Boston-based life science venture capital firm where she led numerous therapeutic and diagnostic investments within the $1 billion portfolio of 149 companies.

Ellen previously served as Senior Vice President, Business Development at Human Genome Sciences, a publically traded biopharmaceutical company where she was responsible for all business functions of the Company including corporate partnering, licensing and investor interface.

Ellen previously had spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. She has over 30 years of operating and investment expertise across the spectrum of the pharmaceutical and biotechnology industries, with particular emphasis in oncology, neurology, and infectious disease. Ellen holds a Ph.D. in Microbiology from Georgetown University School of Medicine and a post-doctorate at the Public Health Research Institute in New York.

Paul Mieyal, Ph.D., CFA

Managing Director
Paul Mieyal, Ph.D., CFA

Paul Mieyal, Ph.D., CFA

Managing Director LinkedIn

Dr. Mieyal is a Managing Director  with over 20 years of public and private early-stage life sciences investment and operational experience.

Prior to joining Outcome Capital, Dr. Mieyal most recently served as Managing Director of Life Sciences Investments at Wexford Capital. He was previously Vice President of Wechsler & Co., a broker-dealer and proprietary investment firm.

Dr. Mieyal has served as a director or observer on the boards of numerous life sciences companies, including AZTherapies, Danube Pharmaceuticals, Ellipse Technologies, ElMinda Ltd, GlobeImmune, Interventional Spine, Invuity (IVTY), MiCardia, Microbiogen Pty, Nephros (NEPH), Nile Therapeutics (NLTX), OncoVista (OVIT), Onset Medical, Optiscan Biomedical, Pear Tree Pharmaceuticals, Rebound Therapeutics, Reverse Medical, Shape Memory Therapeutics, Sophono, Tigris Pharmaceuticals, and Viseon.

From 2010 to 2012, Dr. Mieyal served as the CEO of publicly-traded Nephros, Inc. (NEPH), during which period, he completed strategic in-licensing and out-licensing transactions for the company’s products and led negotiations with the FDA which resulted in the clearance of the company’s hemodiafiltration system in the U.S.

Dr. Mieyal earned his Ph.D. in Pharmacology from New York Medical College and his B.A. in Chemistry and Psychology from Case Western Reserve University. He is a Chartered Financial Analyst and a member of the CFA Institute, the CFA Society of Boston, and the New York Academy of Sciences. He is a FINRA Registered Securities Representative holding  Series 79, 7 and 63 registrations.

Karl Hess

Managing Director
Karl Hess

Karl Hess

Managing Director LinkedIn

Karl Hess is a Managing Director with Outcome Capital and leads its HealthTech and digital health practices. Having interacted extensively with hundreds of digital health companies over the years, as well as with dozens of their healthcare and life sciences investors, customers and partners, Karl has become known as a leading subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies. From pharmaceuticals to medical devices and software (SaMD), digital health tools and therapeutics and health optimization and population health management platform technologies to entire care delivery ecosystems, Karl has helped design, develop and commercialize dozens of innovative products and services across the healthcare and life sciences industries, representing hundreds of millions of dollars in incremental revenues and more than $20B in value-unlocking transactions.

Karl also serves as Managing Director of OnDigitalHealth Consulting, LLC, a specialized strategy consulting firm which he founded to serve the burgeoning and rapidly diversifying digital health industry, serving clients across the healthcare and life sciences spectrum. Karl is also a Consulting Advisor to Novo Holdings, A/S, via its U.S. subsidiary, Novo Ventures. Prior to Outcome Capital, Karl was most recently Interim President and CEO of Texas Health | Aetna, a joint venture (and commercial health plan entity) of Texas Health Resources and Aetna, a CVS Health Company. Karl was formerly CEO of Kalico Partners, LLC, a technology-enabled provider and population health management organization (PHMO), and Chief Digital Health Officer of Collain Healthcare, a former subsidiary of LG CNS. Prior to Collain, Karl held the role of Vice President, Corporate Development at Welltok, Inc., a digital health and wellness company revolutionizing the way population health managers align consumer actions and behaviors with the right incentives and rewards. In one of his earliest digital health endeavors, Karl was a key member of the commercial team at Welldoc, Inc., helping to bring Welldoc’s BlueStar platform to market, one of the world’s first, and most successful, digital therapeutics. Earlier in his career, Karl worked for several start-up and Fortune 500 molecular diagnostics, biopharmaceutical, medical technology companies and consulting firms including Genentech, Becton Dickinson and PRTM, principally across product development and management, and market, business and corporate development, licensing and M&A.

Over the years Karl has had the opportunity to participate in two successful exits as an entrepreneur and work on and lead projects for 9 of the Top 20 pharmaceutical companies, 11 of the Top 20 medical device firms and 4 of the Top 25 PE firms, and has had global management responsibilities of leading extended teams of up to 500 and ~$300MM P&L.

Karl began his career as a life sciences researcher, conducting pre-clinical cancer and human genetics research at The University of Texas Southwestern Medical Center, and biotechnology R&D for what are now several subsidiaries of Thermo Fisher Scientific, Inc. Karl received a B.A. in Biology and an M.B.A. both from The University of Texas at Austin. He is a FINRA Registered Securities Representative holding Series 79 and 63 registrations.

Craig A. Steger

Director
Craig A. Steger

Craig A. Steger

Director LinkedIn

Craig is a Director of Life Sciences at Outcome Capital and brings corporate and commercial expertise in the diagnostic and life science space.  A business leader with extensive global experience in the life sciences and healthcare industries, Craig has held various executive positions from start-up companies through large, well-established international corporations.  His success building commercially viable and sustainable enterprises has lead to the completion of several successful acquisitions over the past several years including Caliper Life Sciences, HandyLab and BioHelix. In addition to his role as Vice President of Life Sciences at Outcome Capital, Craig also volunteers with mentoring activities for Women in Biotech and as an Advisor to Springboard Enterprises.

Craig’s scientific background and business experience spans sales, marketing, business development, licensing, strategic partnerships and operations.  His key successes include developing and launching new businesses at Fisher Healthcare, HandyLab, Becton Dickinson and Caliper Life Sciences within the diagnostic market space.  Craig’s knowledge of the diagnostic and life science tools markets has allowed him to develop markets across the globe and leverage strategic partnerships to further market expansion for many of his clients.

Craig holds a Bachelor of Science from the University of Wisconsin – Madison and a Master of Science from Yale University.  He is a FINRA Registered Securities Representative holding  Series 79 and 63.

Thomas F. Busby, III

Senior Vice President
Thomas F. Busby, III

Thomas F. Busby, III

Senior Vice President LinkedIn

Thomas Busby is a Senior Vice President at Outcome Capital, having joined the Firm in 2015. With transactional experience spanning the breadth of life science verticals, Thom’s primary coverage and focus spans the medical device, digital health, and life sciences services segments. In this capacity, Thom has advised dozens of management teams on a variety of complex strategic issues ranging from transaction process considerations to valuation and transaction structure maximization, to value proposition communication and buyer analysis, along with the plethora of managerial challenges faced in executing complex corporate events. Devoted to the industry he serves, Thom has been published in leading industry publications, including: MedTech Strategist, Life Science Leader, and The Pharma Letter. Thom has also served as a panelist and moderator for numerous industry events and is a Board Member of HealthTech Build, a Boston-based digital health innovation group.

Prior to his career in investment banking, Thom pursued his passion for the public service and non-profit sectors. He raised significant capital for many education-related ventures while holding management and leadership positions. At one time, he also held a Massachusetts teaching license.

Thom completed his MBA at Suffolk University on full academic scholarship. He was voted president of the School’s business association and served as class speaker. Prior, he completed a BS in Philosophy at Suffolk’s Honors college. Committed to giving back, Thom served as a two-term President for the University’s Alumni Board of Directors. Thom is a FINRA Registered Securities Representative holding his Series 79, 63 and SIE.

Michaele M. Esdale, Ph.D., CPA

Chief Financial Officer and Vice President of Operations
Michaele M. Esdale, Ph.D., CPA

Michaele M. Esdale, Ph.D., CPA

Chief Financial Officer and Vice President of Operations LinkedIn

Dr. Michaele Esdale is Vice President for Finance and Operations bringing extensive experience in financial leadership. She is a CPA with over twenty years of experience in accounting and taxation advisory in a variety of roles spanning public and private accounting, and training for those in pursuit of continuing and executive education.

Prior to joining Outcome Capital, Dr. Esdale spent nearly two decades in academia with academic positions as assistant professor of Accounting at Northeastern University and full professor of Accounting at Suffolk University, where she was also the director of the Executive MBA program and Suffolk’s Center for Executive Education. Dr. Esdale has over 30 publications in both academic and professional journals, and her research interests include corporate income tax and the effect of tax policy on taxpayer behavior. She was ranked as the #2 behavioral tax researcher in the United States for 2019 and served for several years as the editor for Issues in Accounting Education, the top-ranked accounting education journal.

Concurrent to her time in academia, Dr. Esdale was a national tax instructor for PwC and KPMG, where she taught a wide variety of topics including mergers and acquisitions, corporate tax and the ins and outs of net operating losses. For over a decade, she was the Director of a low-income tax preparation center for Boston-area residents and international students.

Dr. Esdale’s operational expertise includes a CFO and COO positions for a technology company which provided clinical trial data-sharing software to multinational pharmaceutical companies. She was also the Associate Vice President for Career Advising and Professional Development at Merrimack College where she managed a team of advisors and connected students across all disciplines to employers and provided the tools for career development. She is a 2019 Boston Business Journal 40 Under 40 Honoree.

Dr. Esdale earned her undergraduate and graduate degree in accounting at West Texas A&M University and worked in public accounting in Texas before pursuing her PhD at Texas Tech University. She is a FINRA Registered Representative holding  Series 27  and Series 7 registration.

Nicholas Frame, Ph.D.

Vice President
Nicholas Frame, Ph.D.

Nicholas Frame, Ph.D.

Vice President LinkedIn

Dr. Nicholas Frame is a  Vice President in the life sciences practice at Outcome Capital bringing a unique combination of scientific, strategic and transactional expertise. A scientist by training with a focus in amyloid and cardiovascular diseases, Dr. Frame has published multiple first-author manuscripts and received pre-doctoral training grants to advance his research. Shifting his focus to life science innovation and development, Nick has advised numerous medical device, biopharma, diagnostics and services companies on their go-to-market strategies as it relates to capital raise, partnering and M&A transactions

Seeking to support others navigating the transition from academia to industry roles, Nick has mentored numerous undergraduate and doctoral students from leading programs including Harvard University, Johns Hopkins University, and Boston University among others.

Nick holds a B.A. from Johns Hopkins University in biophysics and earned his Ph.D. in biophysics from Boston University School of Medicine. Nick is a FINRA Registered Securities Representative holding his Series 7, 79 and 63.

Michael Casasanta, Ph.D.

Associate
Michael Casasanta, Ph.D.

Michael Casasanta, Ph.D.

Associate LinkedIn

Dr. Michael Casasanta is an Associate at Outcome Capital. He trained as a research scientist with broad exposure to cutting-edge infectious disease, and oncology-based technologies.

Dr. Casasanta is a published author with numerous peer-reviewed manuscripts in addition to his significant contributions in several multi-million-dollar NIH-funded grants supporting his research. During his time in research, Dr. Casasanta developed a passion to enrich the personal and professional lives of his colleagues. He served in the Graduate Student Assembly of Virginia Tech and the Student Council of the Microscopy Society of America to provide community building and professional development events for both students and early career professionals. Subsequent to his academic studies, Michael served as a Venture Fellow at Nodes Advisors AG, a European-based corporate advisory firm. There, Dr. Casasanta led due diligence processes evaluating the scientific and economic potential of emerging biotechnology companies while assisting in the preparation of transactional materials for the Fund’s portfolio companies.

Dr. Casasanta received dual B.S degrees in Biology and Biochemistry and earned his Ph.D. in Biochemistry from Virginia Tech’s flagship campus in Blacksburg, VA. He is a FINRA Registered Securities Representative holding Series 7 registrations.

Elena Bonetti

Analyst
Elena Bonetti

Elena Bonetti

Analyst LinkedIn

Elena Bonetti is an Analyst in Outcome Capital’s life science practice . Within her role at Outcome, Elena facilitates extensive market research across multiple verticals including medical device, biotechnology, digital health, diagnostics and life science services. Drawing from deep knowledge of financial markets, Elena assists Outcome’s clients in market sizing, market share analysis and growth outlooks to inform strategic positioning and align technologies with their respective markets. Elena also directly supports Outcome’s clients in their administrative and process-related needs.

Prior to joining Outcome, Elena was a legislative intern for the Commonwealth of Massachusetts. As an active community member and lifelong North End resident, Elena currently serves as a member and financial secretary to several nonprofit and benefit organizations in the Boston area.

Elena completed her BSBA in Finance with a minor in Business Law at Suffolk University, graduating Summa Cum Laude as a Sawyer Business School Honors Scholar. She is a FINRA Registered Securities Representative holding  Series 79  and 63 registration.

Derrick Holmes, CFA

Analyst
Derrick Holmes, CFA

Derrick Holmes, CFA

Analyst LinkedIn

Focusing primarily on medical device, diagnostics and life sciences services transactions, Derrick leverages an expansive financial background in supporting clients’ needs. Previously, Derrick was a Senior Associate at Bank of America in their private wealth portfolio management team. Derrick is a Certified Financial Analyst (CFA) and serves as a member of the CFA Institute and CFA Society of Boston. He has also successfully completed financial modeling and valuation coursework with Wall Street Prep.

Derrick was awarded a BSBA degree in Finance with a minor in Economics from the University of Rhode Island where he was a member of the varsity football team throughout his undergraduate career.

Carey Gallant

Analyst
Carey Gallant

Carey Gallant

Analyst LinkedIn

Carey Gallant is an Analyst in Outcome Capital’s life sciences practice assisting the team in support of a wide range of M&A, corporate finance, and advisory mandates.

Prior to joining Outcome, Carey was an associate in LifeSci Partners’ Investor Relations vertical. While at LifeSci, Carey was responsible for assisting a variety of strategic consulting efforts for early and late-stage healthcare and life sciences companies via tailor-made market research and competitive analysis. Before making his transition into a consulting role, Carey began his career as a life sciences researcher conducting pre-clinical oncology research at Synlogic and Minerva Biotechnologies. During this time, he developed assays to identify anti-inflammatory cytokine marker readouts for immuno-modulation.

Carey received a B.S. in biomedical engineering from the University of Vermont and is currently enrolled in Boston College’s Carroll School of Management pursuing an MBA/MSF dual degree. He has completed financial modeling and valuation coursework with Wall Street Prep.

Senior Advisors

Dalia Cohen, Ph.D.

Senior Advisor
Dalia Cohen, Ph.D.

Dalia Cohen, Ph.D.

Senior Advisor LinkedIn

Dr. Cohen is an accomplished biologist bringing significant drug discovery and development expertise to Outcome Capital, leveraging her academic, pharmaceutical and biotech experience.

In 2017, Dr. Cohen co-founded The RNA Medicine Company and served as the Company’s Chief Scientific Officer (CSO) until 2019. Currently, she remains the scientific advisor of the company. The RNA Medicine Company focuses on identifying small molecules targeting the biogenesis of oncogenic microRNAs. Between 2006 and 2017, Dr. Cohen served as CSO at Beryllium, a specialized target-based protein structure and characterization CRO (acquired by UCB Pharma), Asterand, a global supplier of human tissue and tissue-based research services and Rosetta Genomics, a microRNA-based diagnostic company. During her tenure at Rosetta, three diagnostic tests based on microRNA for differential diagnostics of tumors were developed.

Dr. Cohen also held several executive positions at Novartis, including Vice President and Global Head of Functional Genomics. While at Novartis, Dr. Cohen initiated the Histone Deacetylase Inhibitor program. One of the inhibitors was approved by the FDA for the treatment of Multiple Myeloma. Prior to Novartis, Dr Cohen was an adjunct professor at the UMDNJ-Robert Wood Johnson Medical School.

Dalia is currently a member of the scientific advisory boards of the Massachusetts Life Sciences Center. She holds a Bachelor of Sciences in biology, a Master’s degree in virology and a Doctorate in cell biology from the Israel Institute of Technology. She completed her postdoctoral training at the Albert Einstein College of Medicine.

Don Haut, Ph.D.

Senior Advisor
Don Haut, Ph.D.

Don Haut, Ph.D.

Senior Advisor LinkedIn

Dr. Don Haut brings a broad life-science business perspective to Outcome Capital from senior executive and Board positions in Strategy, M&A, and General Management, with deep domain expertise across multiple disciplines in pharmaceutical, biotech, and medical device industries.  Don is an experienced transaction professional with over $4B in deals to his credit.

Dr. Haut is the Chief Business Officer a Sherlock Bioscience, a molecular diagnostics company. He currently serves on the Board of Directors for three health care companies: MiMecore Therapeutics, Arthrosurface, and Xiros. Prior, he was  Chief Business Officer at Histogenics Corporation and Vice President for New Business Ventures at The Medicines Company, where he was responsible for leading that company’s deal to license Alnylam’s PCSK9 inhibitor. Previously, he was the Senior Vice President for Strategy and Business Development at Smith and Nephew’s Advanced Surgical Devices Division, where he was responsible for all strategy development, M&A and licensing activities, and also built and ran Smith & Nephew’s Women’s Health business. Dr. Haut also previously held similar roles at 3M, JSB Partners and McKinsey and Company.

Don obtained his MBA at Washington University’s Olin School of Business, his PhD in Molecular Biology at the University of Missouri-Columbia, and his undergraduate degree at the College of Wooster.

Paul Juniewicz, Ph.D.

Senior Advisor
Paul Juniewicz, Ph.D.

Paul Juniewicz, Ph.D.

Senior Advisor LinkedIn

Dr. Juniewicz serves as Senior Advisor with Outcome Capital’s Biotechnology and Pharma practices. He brings extensive scientific, strategic and operational expertise in public and private life science companies.

He is currently Senior Director of Business Development at Takeda Pharmaceuticals Oncology Business Unit focusing on late-stage clinical oncology opportunities. Prior to that, Dr. Juniewicz served as Senior Director for Oncology Search & Evaluation in Takeda’s Center for External Innovation (CEI). In this role, he led the scouting of external oncology opportunities as well scientific and technical due diligence for several transactions including, among others, MD Anderson, Turnstone Biologics, Memorial Sloan Kettering Cancer Center, Shattuck Labs, Molecular Templates, Maverick Therapeutics, as well as the Japan licensing of cabozantinib (Exelixis) and niraparib (Tesaro) and the merger and acquisition of Ariad Pharmaceuticals. Based on his accomplishments Paul was awarded the title of Distinguished Research Fellow in Oncology in 2019.

Dr. Juniewicz started his professional career with Sterling Drug as a bench research scientist and then took a position as Oncology Project Manager overseeing several oncology projects. Following the acquisition of Sterling Drug by Sanofi, Paul rose to the role of VP Oncology Project Management and oversaw the development of oncology projects that resulted in global regulatory approvals for several agents including oxaliplatin for colorectal cancer, rasburicase for tumor lysis syndrome and aflibercept for colorectal cancer.

Dr. Juniewicz numerous accomplishments include over 100 external opportunities reviewed with 10+ entering due diligences each year, development of Takeda’s oncology strategy, oncology scouting and partnering activities at AACR, ASCO & ASH, JP Morgan and BIO meetings.

Dr. Juniewicz received a BS from Rutgers University, an MS and a Ph.D. from North Carolina State University. He completed his postdoctoral training at Johns Hopkins University.

Michael Montgomery, MD

Senior Advisor
Michael Montgomery, MD

Michael Montgomery, MD

Senior Advisor

Dr. Montgomery serves as Senior Advisor to Outcome Capital’s Biotechnology and Pharma practice. He brings extensive expertise in bench-top molecular biology research, clinical practice, drug development and marketing in both biotech and Big Pharma. He has developed several database solutions in the field of project management, resulting in two J&J  IMAGE awards, and has spoken at multiple events on the successful application of software and data management solutions to real world medical problems. He has designed and run both US and Global Phase 2, 3 and 3b trials in cardiovascular disease, peripheral vascular disease, stroke, inflammatory diseases and the first Phase 4 Registry in Polycythemia Vera, REVEAL. He holds a key patent in the use of JAK1 inhibitors. Dr. Montgomery also led Incyte Corporation’s Global Medical Affairs department that he helped create. He has been CMO of both Caduceus Communications LLC, a clinical communications company and Lead Horse Technologies Inc., an AI company. He currently sits on the PhRMA Foundation Translational Medicine Grant Review Board and is a Co-Founder of Stable Solutions LLC, a medical and machine learning consultancy.

In addition to his experience in the biotech and pharma sectors, Dr. Montgomery’s medical and research career includes attending physician at Parkland and Dallas Veterans Hospitals, Cardiology Research Fellow at Washington University School of Medicine and Associate Professor at Temple Medical School Department of  Anatomy & Cell Biology. Dr. Montgomery is widely published in peer-reviewed medical and scientific journals on various topics including stroke, peripheral and arterial vascular disease, dermatology and oncology. He received his MD from Columbia University College of Physicians and BSc degree from McGill University.

J. Chuck Morrison BS, MBA

Senior Advisor
J. Chuck Morrison BS, MBA

J. Chuck Morrison BS, MBA

Senior Advisor LinkedIn

Chuck Morrison serves as a Senior Advisor at Outcome Capital’s diagnostics and biotechnology practices. He brings significant expertise and a track record in successfully structuring, negotiating and executing acquisitions, licensing, partnerships, and distribution transactions. Chuck is a business development executive with over thirty years of life science, biotechnology and diagnostic expertise, including 13 years of corporate business development. He is a leader in the life science sector with proven business acumen, international experience, integrity, strategic vision and focus on execution. Known for driving results and overcoming difficult challenges.

Chuck is currently a non-executive Board Member for GenePOC, Inc., a molecular diagnostic company developing point-of-care platforms for the rapid detection of infectious diseases (recently acquired by Meridian Bioscience). He is also Head of Business Development at Proteomics International, Perth, Australia. PI has developed a proprietary mass spectrometry biomarker discovery platform and has recently discovered biomarkers for the diagnosis of diabetic kidney disease. Previously, Chuck held various managerial positions at PerkinElmer, NEN Life Sciences and DuPont Medical Products.

Chuck is currently providing strategic consulting services to early-stage and smaller biotech companies, positioning toward merger & acquisitions, partnerships, licensing and joint ventures, as well as team building, product commercialization and carving out a path to commercialization.

Cathy A. Petti, MD

Senior Advisor
Cathy A. Petti, MD

Cathy A. Petti, MD

Senior Advisor LinkedIn

Dr. Petti serves as Senior Advisor to Outcome Capital’s diagnostics and digital health practices. She is a health technology executive and diagnostics expert with a unique combination of clinical, scientific and operational expertise, focusing her efforts in the molecular diagnostics, genomics and digital health verticles. She serves as a strategic, interim Chief Medical Officer providing companies with top-down market perspective and an extensive thought leader network. Dr. Petti supports strategic corporate activities related to technology assessments, clinical trial and regulatory strategies, and pathways to commercialization. She has assisted numerous companies across the value-add chain, successfully facilitating private equity financings, government contracts and merger and acquisition transactions amounting to hundreds of millions of dollars. She serves on the Advisory Boards for Pathogenomix, Life365, and Becton Dickinson. As an entrepreneur supporting innovative early-stage technologies, Dr. Petti founded MoDx.ai, a knowledge domain platform integrating diagnostics, digital health and Artificial Intelligence.

Among her senior executive roles, Dr. Petti served as Global Head at Novartis Diagnostics where she was responsible for expanding global markets for their core products and building R&D teams for three de novo franchises. As Chief Health Officer at Ancestry, Dr. Petti built a direct-to-consumer genetic testing portfolio and served on the executive team that led to private equity investments at enterprise value of $2.6 billion. She also led ARUP Infectious Diseases Laboratory, one of the country’s largest infectious diseases laboratories and pioneered research in DNA sequencing.

Dr. Petti shares her expertise and leadership with several global non-profit organizations and regulatory agencies, including having chaired committees for the Clinical and Laboratory Standards Institute; served as program lead for Infectious Diseases Society of America; and advised the FDA Microbiology Device Committee. Previously, Dr. Petti was a Governor Appointee and member of the Board of Directors for Utah’s Science, Technology and Research (USTAR) Initiative. Committed to underserved populations, she received the College of American Pathologists’ Humanitarian Award for her work in providing diagnostic testing in sub-Saharan Africa;was awarded the 2015 ASM-IUSSTF Indo-US Professorship in Microbiology; and served as 2019 Visiting Professor to Infectious Diseases Institute, Kampala, Uganda.

As a practicing infectious diseases clinician, Dr. Petti provides a critically relevant understanding of healthcare drivers for adoption of new technologies. She has held academic appointments as Professor of Medicine and Pathology at leading institutions; and is frequently invited to speak on topics in clinical diagnostics, healthtech innovations, global health, and women’s entrepreneurship. Dr. Petti holds an AB from Harvard University and MD from Duke University. She is an internist, and dual board certified in infectious diseases and medical microbiology.

Caroline Popper MD MPH

Senior Advisor
Caroline Popper MD MPH

Caroline Popper MD MPH

Senior Advisor LinkedIn

Dr. Popper serves as Senior Advisor in Outcome Capital’s molecular diagnostics and biotechnology practices. She brings significant expertise and track record in positioning novel technologies toward successful implementation and commercialization. Dr. Popper is also the Co-Founder and President of Popper and Company, a specialty consulting firm focused in diagnostics, information-generating tools and healthcare analytics, where she and her team leverage their extensive knowledge of the trends and forces shaping the life sciences industry and its participants.

Dr. Popper has more than 25 years of hands-on biotech/life sciences operating experience. An internist and pathologist, she combines medical and scientific perspective with knowledge gained from managing a wide spectrum of life sciences businesses in diagnostics, devices and drug discovery. Her business management experience in both Fortune 500 and start-up settings – and extensive track record creating strategic and business partnerships in the biotech arena – is key to the insights she provides to her clients.

During a 10-year career at Becton Dickinson (NYSE: BDX), Dr. Popper’s global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding General Manager of BDGene, a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. Subsequently, she was the Chief Business Officer for MDS Proteomics, a drug discovery company with operations in the U.S., Canada and Europe.

Dr. Popper received her medical degree from the University of the Witwatersrand (South Africa) and her M.P.H. from Johns Hopkins University (Baltimore). She completed her residencies in internal medicine and in pathology at Johns Hopkins. Dr. Popper is and Advisory Board member of the Bloomberg Johns Hopkins School and Public Health and inHealth, the Hopkins Precision Medicine Initiative. She is a board member of Diversigen (a microbiome-based company) and LBT Innovations (an Australian AI-based lab automation company).

Herbert Torfs, Ph.D., EMBA

Senior Advisor
Herbert Torfs, Ph.D., EMBA

Herbert Torfs, Ph.D., EMBA

Senior Advisor LinkedIn

Dr. Torfs serves as a Senior Advisor at Outcome Capital’s diagnostic and medical device practices. He brings signifiant expertise and track record in marketing and business development with over 20 years experience. Dr. Torfs is passionate about propelling innovative products and technologies to drive change through increased access, quality of care and accurate diagnostics where and when it matters most.

Dr. Torfs operational experience spans from early-stage innovative companies to large multi-national strategic players where he launched multiple products in the EMEA region and worldwide. Many of those products resulted in a paradigm shift in diagnostic practices, based on health economic evidence and improved diagnostics for better patient outcomes.

Dr. Torfs is also the Founder and President of DIATOR BVBA, a consulting firm supporting early stage marketing during product development, guiding early market access and devising Go-To-Market strategies. DIATOR also provides interim management and strategic consulting services to early-stage biotech and diagnostic companies.

Herbert holds an MSc in Biology and Ph.D. in Physiology and Molecular Biology, both from the Catholic University of Leuven, Belgium, and an EMBA from Hult-Ashridge Business school London Campus.

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    99 High St. Suite 2900, Boston, MA 02110
    (617) 431-2278